```
=> d his

     (FILE 'HOME' ENTERED AT 16:33:18 ON 05 JAN 2007)

     FILE 'USPATFULL, CAPLUS' ENTERED AT 16:33:45 ON 05 JAN 2007
L1             7 FILE USPATFULL
L2           752 FILE CAPLUS
     TOTAL FOR ALL FILES
L3           759 S (FIBRINOGEN (1S) LIPID?)/AB
L4             5 FILE USPATFULL
L5            58 FILE CAPLUS
     TOTAL FOR ALL FILES
L6            63 S L2 AND COMPOSITION
L7             2 FILE USPATFULL
L8             0 FILE CAPLUS
     TOTAL FOR ALL FILES
L9             2 S FIBRIN GEL AND L6
L10            3 FILE USPATFULL
L11            1 FILE CAPLUS
     TOTAL FOR ALL FILES
L12            4 S FIBRIN AND GLUE AND L6
L13            1 FILE USPATFULL
L14            1 FILE CAPLUS
     TOTAL FOR ALL FILES
L15            2 S L12 NOT L9
L16           45 FILE USPATFULL
L17            0 FILE CAPLUS
     TOTAL FOR ALL FILES
L18           45 S (FIBRINOGEN (1S) LIPID?)/CLM

=>  save all temp
ENTER NAME OR (END):l10664561/l
L# LIST L1-L18 HAS BEEN SAVED AS 'L10664561/L'

=>
```

L3 ANSWER 6 OF 759 USPATFULL on STN

AB High purity antithrombin III is recovered from a procedure in which the other protein fractions in human blood plasma are recovered for further processing. The protein fractions are recovered sequentially in separate steps: **fibrinogen** and Factor VIII are recovered as a precipitate; prothrombin complex is recovered on the surface of finely divided tricalcium phosphate; albumin and gamma globulin are recovered in an aqueous supernate; a protein precipitate containing **lipids**, lipoproteins and other trace protein contaminants is recovered; and antithrombin III is recovered as a precipitated phase. The **fibrinogen**, Factor VIII, prothrombin complex, albumin, gamma globulin and protein contaminants are all recovered in such a way that they are suitable for further processing.

ACCESSION NUMBER:	78:22825 USPATFULL
TITLE:	Antithrombin III
INVENTOR(S):	Bick, Rodger L., Los Angeles, CA, United States Fekete, Lajos F., Costa Mesa, CA, United States
PATENT ASSIGNEE(S):	Wilson, William L., Santa Monica, CA, United States (U.S. individual) Bick, Rodger L., Santa Monica, CA, United States (U.S. individual) Fekete, Lajos F., Santa Monica, CA, United States (U.S. individual)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4087415		19780502	
APPLICATION INFO.:	US 1976-694167		19760609	(5)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Danison, Walter C.
LEGAL REPRESENTATIVE:	Hubbell, Cohen, Stiefel & Gross
NUMBER OF CLAIMS:	4
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)

L6 ANSWER 63 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN

TI The lipide content and the electrophoretic determination of the protein **composition** of serum and the fibrinogen content of the plasma in leprosy

AB . . . albumin 54.5-60.2, 35.1-49.1; α-globulin 5.1-7.5, 5.4-13.3; β-globulin 12.5-15.8, 11.1-13.3; γ-globulin 20.6-24.8, 28.7-45.4; and total globulin 39.8-45.5, 50.9-64.9%, resp. The serum **lipide** concns. were as follows: total fatty acids 469-701 in I, 618-1111 mg. % in II; total cholesterol 120-195, 137-195 mg.. . . 48-70% of the total cholesterol; phosphatide 57-157, 41-210 mg. %; and neutral fatty acids 341-638, 484-926 mg. %, resp. The **fibrinogen** content of the plasma was 0.51-0.96% in I and 0.43-0.58 in II. The thymol turbidity reaction was increased and the. . .

ACCESSION NUMBER:	1953:7040 CAPLUS
DOCUMENT NUMBER:	47:7040
ORIGINAL REFERENCE NO.:	47:1273f-h
TITLE:	The lipide content and the electrophoretic determination of the protein **composition** of serum and the fibrinogen content of the plasma in leprosy
AUTHOR(S):	Patiala, Risto; Raekallio, Tapio
CORPORATE SOURCE:	Univ. Helsinki, Finland
SOURCE:	Ann. Med. Exptl. et Biol. Fenniae (1951), 29, 335-9
DOCUMENT TYPE:	Journal
LANGUAGE:	German

=>

L6 ANSWER 54 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN

AB The following mean values (mg%) were found in Jaffarabadi buffalo cows: **fibrinogen** 1206, total **lipids** 816, cholesterol 115, and urea 24.4.

ST blood buffalo normal **compn**; lipid cholesterol blood buffalo; fibrinogen blood buffalo

IT Buffalo
(blood **compn**. of)

IT Blood
(of buffalo, **compn**. of)

ACCESSION NUMBER:	1974:423627 CAPLUS
DOCUMENT NUMBER:	81:23627
TITLE:	Total lipids, cholesterol, urea, and fibrinogen in the blood of buffalo
AUTHOR(S):	Antunes de Alencar Filho, Rufino
CORPORATE SOURCE:	Sec. Patrol. Clin., Inst. Biol., Sao Paulo, Brazil
SOURCE:	Biologico (1973), 39(9), 223-4 CODEN: BIOGAL; ISSN: 0366-0567
DOCUMENT TYPE:	Journal
LANGUAGE:	Portuguese

L6 ANSWER 45 OF 63 CAPLUS COPYRIGHT 2007 ACS on STN
TI Pharmaceutical **composition** for preventing pathological processes
AB . . . by i.v. injection of 15 mg rat fibrinogen. Labeled fibrinogen injected i.v. was transported to the site of inflammation. Human **fibrinogen** was inactive in rats. The antiinflammatory agent phenylbutazone (I) [50-33-9], injected s.c. (200 mg/kg) into rats with inflammation induced by carrageenan or **lipid** A, enhanced the elevation of certain plasma proteins above that seen in rats with inflammation which did not receive I,. . .

ACCESSION NUMBER: 1979:61229 CAPLUS
DOCUMENT NUMBER: 90:61229
TITLE: Pharmaceutical **composition** for preventing pathological processes
INVENTOR(S): Ruhenstroth-Bauer, Gerhard; Scherer, Reiner
PATENT ASSIGNEE(S): Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V., Fed. Rep. Ger.
SOURCE: Ger. Offen., 27 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2722769	A1	19781123	DE 1977-2722769	19770520
DE 2722769	B2	19801009		
DE 2722769	C3	19810806		
GB 1603244	A	19811118	GB 1978-18751	19780510
US 4215109	A	19800729	US 1978-906442	19780517
CH 644762	A5	19840831	CH 1978-5384	19780518
JP 54017107	A	19790208	JP 1978-59873	19780519
JP 63041890	B	19880819		

PRIORITY APPLN. INFO.: DE 1977-2722769 A 19770520
DE 1977-2750920 A 19771115

S PATENT.

L15 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

AB . . . for their production and use thereof. Disclosed are tissue sealants supplemented with at least one cytotoxin or cell proliferation inhibiting **compn**. The **compn**. may be further supplemented with, for example, one or more antibodies, analgesics, anticoagulants, anti-inflammatory compds., antimicrobial **compns**., cytokines, drugs, growth factors, interferons, hormones, **lipids**, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like. Heparin binding growth factor-1 (HBGF-1) was added at 10 μg in a **fibrinogen** complex containing heparin 10, thrombin 0.5 U/mL, and CaCl2 40 mM for testing the HBGF-1 diffusion from a **fibrin glue** clot.

ST **fibrin** tissue sealant supplement

IT Antibodies
Bone morphogenetic proteins
Cytokines
DNA
Fibrinogens
Fibrins
Fibronectins
Growth factors, animal
Hormones, animal, biological studies
Interferons
Lipids, biological studies
Mineral elements, biological studies
Oligonucleotides
Peptides, biological studies
Platelet-derived growth factors
Polynucleotides
Polysaccharides, biological studies
Proteins, general, biological studies
Proteoglycans, biological studies
RNA
Steroids, biological studies
Transforming growth factors
Vitamins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(supplemented and unsupplemented tissue sealants)

ACCESSION NUMBER: 2000:636163 CAPLUS
DOCUMENT NUMBER: 133:227868
TITLE: Supplemented and unsupplemented tissue sealants, method of their production and use
INVENTOR(S): MacPhee, Martin James; Drohan, William Nash; Liau, Gene; Haudenschild, Christian
PATENT ASSIGNEE(S): The American National Red Cross, USA
SOURCE: U.S., 79 pp., Cont.-in-part of U.S. Ser. No. 351,006, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6117425	A	20000912	US 1995-474086	19950607
EP 1142581	A2	20011010	EP 2001-113651	19911127
EP 1142581	A3	20020911		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AU 9884192	A	19981105	AU 1998-84192	19980911

AU 733471	B2	20010517			
US 39192	E1	20060718	US 2003-465854		20030620
JP 2006297130	A	20061102	JP 2006-178637		20060628
PRIORITY APPLN. INFO.:			US 1990-618419	B2	19901127
			US 1991-798919	B2	19911127
			US 1993-31164	B1	19930312
			US 1994-328552	B2	19941025
			US 1994-351006	B2	19941207
			EP 1992-901268	A3	19911127
			AU 1994-63648	A3	19940314
			JP 1994-520353	A3	19940314
			US 1995-474086	A	19950607

REFERENCE COUNT: 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 39 OF 45 USPATFULL on STN

CLM What is claimed is:

1. A liposome wherein a hemostatically effective amount of a C.sub.8 -C.sub.20 acylated **fibrinogen** is covalently incorporated into the **lipid** bilayer of said liposome.

ACCESSION NUMBER:	97:73304 USPATFULL		
TITLE:	Fibrinogen-coated liposomes		
INVENTOR(S):	Retzinger, Gregory Scott, Cincinnati, OH, United States Deanglis, Ashley P., Cincinnati, OH, United States		
PATENT ASSIGNEE(S):	University of Cincinnati, Cincinnati, OH, United States (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5658588		19970819
APPLICATION INFO.:	US 1995-414368		19950331 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kishore, Gollamudi S.		
LEGAL REPRESENTATIVE:	Frost & Jocobs		
NUMBER OF CLAIMS:	36		
EXEMPLARY CLAIM:	1		
LINE COUNT:	760		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 36 OF 45 USPATFULL on STN

CLM What is claimed is:

. . . an antiangiogenin, an antifibrinolytic compound, an antimicrobial compound, an antiparasitic agent, an antiseptic, an antiviral compound, a chemotherapeutic drug, a **lipid** or liposome, an oligonucleotide or polynucleotide, an osteoconductive compound, a polysaccharide, a vasoconstrictor, a vasodilator, a vitamin, a nutritional supplement and a mineral; and (ii) **fibrinogen** in an amount which forms a fibrin matrix; wherein said fibrinogen forms a fibrin matrix when in the presence of. . .

ACCESSION NUMBER:	2000:121069 USPATFULL
TITLE:	Supplemented and unsupplemented tissue sealants, method of their production and use
INVENTOR(S):	MacPhee, Martin James, Gaithersburg, MD, United States Drohan, William Nash, Springfield, VA, United States Liau, Gene, Darnestown, MD, United States Haudenschild, Christian, Rockville, MD, United States
PATENT ASSIGNEE(S):	The American National Red Cross, Falls Church, VA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6117425		20000912
APPLICATION INFO.:	US 1995-474086		19950607 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-351006, filed on 7 Dec 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-328552, filed on 25 Oct 1994, now abandoned which is a continuation of Ser. No. US 1993-31164, filed on 12 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1990-618419, filed on 27 Nov 1990, now abandoned which is a continuation-in-part of Ser. No. US 1991-798919, filed on 27 Nov 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Woodward, M Patrick		
ASSISTANT EXAMINER:	Zeman, Mary K		
LEGAL REPRESENTATIVE:	Sterne, Kessler Goldstein & Fox P.L.L.C.		
NUMBER OF CLAIMS:	57		
EXEMPLARY CLAIM:	1,2,3		
NUMBER OF DRAWINGS:	53 Drawing Figure(s); 36 Drawing Page(s)		
LINE COUNT:	4910		

L18 ANSWER 35 OF 45 USPATFULL on STN

CLM What is claimed is:

. . . decreasing blood loss by intravenous injection, said method comprising administering to a subject a particle comprising a biocompatible matrix with **fibrinogen** within or on the surface of said particle, said biocompatible matrix selected from the group consisting of proteins, **lipids**, nucleic acids, and carbohydrates.

. . . due to the action of thrombin, said method comprising administering to a subject a particle comprising a biocompatible matrix with **fibrinogen** within or on the surface of said particle, said biocompatible matrix selected from the group consisting of proteins, **lipids**, nucleic acids, and carbohydrates.

ACCESSION NUMBER: 2002:258479 USPATFULL
TITLE: Protein particles for therapeutic and diagnostic use
INVENTOR(S): Yen, Richard C.K., Yorba Linda, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002142046	A1	20021003
APPLICATION INFO.:	US 2002-42834	A1	20020108 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-952765, filed on 10 Apr 1998, GRANTED, Pat. No. US 6391343 A 371 of International Ser. No. WO 1996-US9458, filed on 4 Jun 1996, UNKNOWN A 371 of International Ser. No. US 1995-471650, filed on 6 Jun 1995, GRANTED, Pat. No. US 5725804 A 371 of International Ser. No. US 1995-554919, filed on 9 Nov 1995, PENDING A 371 of International Ser. No. US 1995-471650, filed on 6 Jun 1995, GRANTED, Pat. No. US 5725804 Continuation-in-part of Ser. No. US 1994-212546, filed on 14 Mar 1994, GRANTED, Pat. No. US 5616311 Continuation-in-part of Ser. No. US 1993-69831, filed on 1 Jun 1993, ABANDONED Continuation-in-part of Ser. No. US 1992-959560, filed on 13 Oct 1992, GRANTED, Pat. No. US 5308620 Continuation-in-part of Ser. No. US 1991-641720, filed on 15 Jan 1991, ABANDONED

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 63
EXEMPLARY CLAIM: 1

L18 ANSWER 34 OF 45 USPATFULL on STN

CLM What is claimed is:

. . . means for stabilizing an agent, which is for measuring a extrinsic coagulation factor for blood coagulation function, comprising at least **fibrinogen**, Factor V, and thromboplastin or **lipidated** tissue factor, characterized by inhibiting biological function for Factor XIII.

6. An agent, which is for measuring a extrinsic coagulation factor for blood coagulation function, comprising at least **fibrinogen**, Factor V, and thromboplastin or **lipidated** tissue factor, characterized by inhibiting biological function for Factor XIII, or characterized by being stabilized by adding effective amount of. . .

ACCESSION NUMBER:	2003:64751 USPATFULL			
TITLE:	Means of stabilizing compositions and reagents			
INVENTOR(S):	Okuda, Masahiro, Kobe-shi, JAPAN Hiura, Hisahide, Kobe-shi, JAPAN			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003044872	A1	20030306	
APPLICATION INFO.:	US 2002-168756	A1	20020618	(10)
	WO 2000-JP9131		20001222	
	NUMBER		DATE	
PRIORITY INFORMATION:	JP 1999-366663		19991224	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	Luke A Kilyk, Kilvk & Bowersox, 53 A East Lee Street, Warrenton, VA, 20186			
NUMBER OF CLAIMS:	6			
EXEMPLARY CLAIM:	1			
LINE COUNT:	400			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L18 ANSWER 33 OF 45 USPATFULL on STN

CLM What is claimed is:

. . . an antiviral compound, a cytokine, a cytotoxin or cell proliferation inhibiting compound, a chemotherapeutic drug, a hormone, an interferon, a **lipid**, an oligonucleotide, a polysaccharide, a protease inhibitor, a proteoglycan, a polypeptide, a steroid, a vasoconstrictor, a vasodilator, a vitamin, and a mineral, and (ii) **fibrinogen**, or a derivative or metabolite thereof, in an amount which forms a fibrin matrix; and (b) applying said supplemented tissue. . .

ACCESSION NUMBER: 2003:123327 USPATFULL

TITLE: Method of preparing a tissue sealant-treated biomedical material

INVENTOR(S): Burgess, Willson H., Gaithersburg, MD, United States
Greisler, Howard P., Chicago, IL, United States
Drohan, William N., Springfield, VA, United States
Maciag, Thomas, Rockville, MD, United States
MacPhee, Martin J., Gaithersburg, MD, United States

PATENT ASSIGNEE(S): Loyola University of Chicago, United States (U.S. corporation)
The American National Red Cross, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6559119	B1	20030506
APPLICATION INFO.:	US 1995-486048		19950607 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-351006, filed on 7 Dec 1994, now abandoned Continuation-in-part of Ser. No. US 1994-328552, filed on 25 Oct 1994, now abandoned Continuation of Ser. No. US 1993-31164, filed on 12 Mar 1993, now abandoned Continuation-in-part of Ser. No. US 1990-618419, filed on 27 Nov 1990, now abandoned Continuation-in-part of Ser. No. US 1991-798919, filed on 27 Nov 1991, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Witz, Jean C.
LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox, P.L.L.C.
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 50 Drawing Figure(s); 36 Drawing Page(s)
LINE COUNT: 4892
CAS INDEXING IS AVAILABLE FOR THIS PATENT.